BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS;American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovas- cular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a sci- entific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009;119:351 357. 297. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care. 1995;18:361 376. 298. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/ EDIC) Study Research Group. Intensive diabetes treatment and car- diovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643 2653. 299. Zhang C, ZhouYH, Xu CL, Chi FL, Ju HN. Efficacy of intensive control of glucose in stroke prevention: a meta-analysis of data from 59197 par- ticipants in 9 randomized controlled trials. PLoS One. 2013;8:e54465. 300. Tuomilehto J, Rastenyte D. Diabetes and glucose intolerance as risk fac- tors for stroke. J Cardiovasc Risk. 1999;6:241 249. 301. Tight blood pressure control and risk of macrovascular and microvas- cular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703 713. 302. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension: Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996;276:1886 1892. 303. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. 